Can a diabetes drug curb chronic Pouch-Related bathroom trips?

NCT ID NCT07756359

Not yet recruiting Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether tirzepatide (Zepbound) can reduce daily bowel frequency in adults with an ileal pouch-anal anastomosis (IPAA) who have chronic high bowel frequency despite standard anti-diarrheal therapy. Participants will be assigned to receive tirzepatide or standard care (loperamide or diphenoxylate/atropine) and will track their symptoms daily. The main goal is to see if tirzepatide helps more people achieve a 30% reduction in bowel movements by week 12.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide (Zepbound), a dual GIP and GLP-1 receptor agonist, given as a subcutaneous injection
What this could lead to: If effective, tirzepatide could offer a new treatment option to reduce frequent bowel movements and improve quality of life for people living with an ileal pouch.
What could go wrong: This is a small early-phase trial, so results may not apply to everyone. Tirzepatide can cause side effects like nausea or digestive issues, and it may not work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BOWEL DISEASES, INFLAMMATORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BOWEL DISEASES, INFLAMMATORY POUCH, ILEAL POUCHES, ILEOANAL

Contacts and locations

Locations

Cedars Sinai Medical Center

Beverly Hills, California, 90211, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Utah

Salt Lake City, Utah, 84112, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.